Activase tPA data

Cost-effectiveness analyses of the South San Francisco company's clot dissolver shows the agent costs $33,678 per year of each life saved, but is cost-effective compared to other medical strategies such as bypass surgery, dialysis, and anti-hypertensive medication.

As published in the New England Journal of Medicine, the cost-effectiveness analysis of the data from the 41,000 patient GUSTO trial counters criticism that the drug is too expensive, considering that it saved only 11 more lives per thousand than the cheaper streptokinase. ...